As it pertains to when we may be able to offer the
Post# of 30067
Posted On: 01/28/2015 6:10:31 PM
As it pertains to when we may be able to offer the Georgetown blood tests to IOU and CLIA, (pharmas and the general public) here are 3 tests that must be completed first, as Gerald has explained and I understand them.
1) ANALYTICAL VALIDATION: Gerald said we are doing this now during the period of our option agreement on the Georgetown tests. This test is similar to the validation Beckton Dickenson did for us in the Fall of 2013. This should only take a couple of months or so.
2) EXPANDED CLINICAL STUDY: Gerald said Georgetown had already started an expanded "less homogenized" study that should be completed within a few months (3 or 4?) This study is comparable to LymPro's LP002 study. This study is going on while we are doing the analytical validation.
3) ICON LAB VALIDATION: This is the 3 month validation that ICON completed for us in December of 2014 that made us officially launched for pharmas doing clinical trials.
All 3 of these tests appear to be able to be completed within 5 months! They can overlap each other. After finishing them, we could offer our complete suite of AD blood tests to pharmas and have "cornered the market." CLIA would not be far behind!
As to accuracy, by having 3 independent tests, it really helps. Even if Lympro's cell cycle were only 85% accurate, and GT's exosome test were 80% accurate, and the lipid test only 75% accurate, if you ran all 3 tests on a patient and they tested positive on all 3, the combined accuracy would be over 99%!!!!! That is HUGE! In other words, we don't need to be all that accurate on any of the 3 tests, because taken together, they are pretty near perfect.
I don't know where the AAIC meeting will be held for the Alzheimer's industry this year. Last year in July it was in Copenhagen. Can you imagine the reception Amarantus will receive if we've completed the above 3 tests for Georgetown and we are offering the entire suite to pharmas for clinical trials? We will steal the show!!
A couple months before the AAIC Conference in Copenhagen, Gerald presented at the Cavendish Gathering. I'll bet they invite him back this year and he'll have an even more compelling story to tell them. They have the billions of dollars needed to bolster our Diagnostic Company's efforts to find a cure for Alzheimers!
The above 3 tests and the time frames given are how I've interpreted what Gerald has said. I think I've got it right.
1) ANALYTICAL VALIDATION: Gerald said we are doing this now during the period of our option agreement on the Georgetown tests. This test is similar to the validation Beckton Dickenson did for us in the Fall of 2013. This should only take a couple of months or so.
2) EXPANDED CLINICAL STUDY: Gerald said Georgetown had already started an expanded "less homogenized" study that should be completed within a few months (3 or 4?) This study is comparable to LymPro's LP002 study. This study is going on while we are doing the analytical validation.
3) ICON LAB VALIDATION: This is the 3 month validation that ICON completed for us in December of 2014 that made us officially launched for pharmas doing clinical trials.
All 3 of these tests appear to be able to be completed within 5 months! They can overlap each other. After finishing them, we could offer our complete suite of AD blood tests to pharmas and have "cornered the market." CLIA would not be far behind!
As to accuracy, by having 3 independent tests, it really helps. Even if Lympro's cell cycle were only 85% accurate, and GT's exosome test were 80% accurate, and the lipid test only 75% accurate, if you ran all 3 tests on a patient and they tested positive on all 3, the combined accuracy would be over 99%!!!!! That is HUGE! In other words, we don't need to be all that accurate on any of the 3 tests, because taken together, they are pretty near perfect.
I don't know where the AAIC meeting will be held for the Alzheimer's industry this year. Last year in July it was in Copenhagen. Can you imagine the reception Amarantus will receive if we've completed the above 3 tests for Georgetown and we are offering the entire suite to pharmas for clinical trials? We will steal the show!!
A couple months before the AAIC Conference in Copenhagen, Gerald presented at the Cavendish Gathering. I'll bet they invite him back this year and he'll have an even more compelling story to tell them. They have the billions of dollars needed to bolster our Diagnostic Company's efforts to find a cure for Alzheimers!
The above 3 tests and the time frames given are how I've interpreted what Gerald has said. I think I've got it right.
(0)
(0)